CST3 and sarcopenia: A combined prospective and retrospective cohort study found that serum cystatin C may be a more accurate marker of renal function in LVAD patients.28 Cystatin C is released by all nucleated cells, not just muscle cells, and is therefore less impacted by the sarcopenia seen in LVAD patients.